Cargando…
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
STUDY QUESTION: What is the safety and efficacy profile during long-term (12–24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associated with uterine fibroids? SUMMARY ANSWER: Uninterrupted tre...
Autores principales: | Diamond, M P, Stewart, E A, Williams, A R W, Carr, B R, Myers, E R, Feldman, R A, Elger, W, Mattia-Goldberg, C, Schwefel, B M, Chwalisz, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6870550/ https://www.ncbi.nlm.nih.gov/pubmed/31777761 http://dx.doi.org/10.1093/hropen/hoz027 |
Ejemplares similares
-
Uterine Fibroids (Leiomyomata) and Heavy Menstrual Bleeding
por: Uimari, Outi, et al.
Publicado: (2022) -
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2021) -
Uterine Fibroids, Perceived Stress, and Menstrual Distress: a Key Role of Heavy Menstrual Bleeding
por: Vannuccini, Silvia, et al.
Publicado: (2022) -
Health Care Costs and Treatment Patterns Associated with Uterine Fibroids and Heavy Menstrual Bleeding: A Claims Analysis
por: Wang, Alice, et al.
Publicado: (2022) -
GnRH analogs for the treatment of heavy menstrual bleeding associated with uterine fibroids
por: Madueke-Laveaux, Obianuju Sandra, et al.
Publicado: (2022)